Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
February 24, 2022 07:00 ET
|
Pluristem Therapeutics, Inc.
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are...
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
January 10, 2022 03:00 ET
|
Pluristem Therapeutics, Inc.
Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and...
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
December 27, 2021 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its...
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
November 15, 2021 07:10 ET
|
Pluristem Therapeutics, Inc.
Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event...
Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform
November 10, 2021 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an...
Pluristem CEO Issues Shareholder Update
September 22, 2021 08:15 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
July 19, 2021 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
July 08, 2021 07:10 ET
|
Pluristem Therapeutics, Inc.
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
May 25, 2021 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
April 29, 2021 07:00 ET
|
Pluristem Therapeutics, Inc.
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...